Evidence database

GLP-1 clinical trials database

Plain-language summaries of every pivotal GLP-1 trial — STEP, SURMOUNT, SURPASS, SUSTAIN, SCALE, AWARD, REWIND, and SELECT. Primary endpoints, effect sizes, and full citations to peer-reviewed publications. Trials cited are for FDA-approved branded products only — compounded GLP-1s have not been studied in equivalent randomized controlled trials.

21
Pivotal trials
51,539
Total participants
12
Years of data (2013–2024)
6
FDA-approved brands

Percent weight loss in pivotal obesity RCTs

Primary-endpoint percent body-weight change at trial end. Bars sorted by effect size. Conducted on FDA-approved branded products only — compounded GLP-1s have not been studied in equivalent RCTs.

Percent weight loss in pivotal obesity RCTs
Trial	NCT ID	Percent weight loss
SURMOUNT-1 · Zepbound	NCT04184622	20.9%
STEP-1 · Wegovy	NCT03548935	14.9%
SCALE Obesity and Prediabetes · Saxenda	NCT01272219	8.0%
SCALE Maintenance · Saxenda	NCT01267617	6.2%

Browse by drug class

Semaglutide

9 trials · 26,379 participants

Tirzepatide

8 trials · 10,529 participants

Liraglutide

2 trials · 4,153 participants

Dulaglutide

2 trials · 10,478 participants

Trial coverage by drug

Drug	Trials	Participants studied	Drug page
Wegovy	7	22,694	/wegovy
Mounjaro	4	5,803	/mounjaro
Zepbound	4	4,726	/zepbound
Ozempic	2	3,685	/ozempic
Saxenda	2	4,153	/saxenda
Trulicity	2	10,478	/trulicity

All trials (21)

GLP1Zoom is an affiliate-only comparator — we cite published trials, we do not conduct them. Each trial entry links to the canonical ClinicalTrials.gov registration and the primary publication. We do not provide medical advice; always discuss treatment decisions with your prescribing clinician. Full disclaimer. Verify any trial at ClinicalTrials.gov.